05:48 PM EDT, 05/07/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q1 non-GAAP diluted earnings of $0.79 a share, up from $0.47 a year earlier.

Analysts polled by Capital IQ expected $0.70.

Revenue in the quarter ended March 31 rose to $195.9 million from $162.1 million a year earlier.

Analysts polled by Capital IQ expected $199.7 million.

In 2024, the company continues to expect non-GAAP diluted EPS of $3.55 to $3.90 on revenue of $915 million to $985 million.

Analysts expect EPS of $3.59 on revenue of $954.4 million.

Price: 41.90, Change: +0.69, Percent Change: +1.67